Juanita Draime

Dr. Juanita Draime

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in Exploratory Research in Clinical and Social Pharmacy
Verified
Journal Article
Open access
ACAleda M. H. Chen
Aleda M. H. Chen
Juanita DraimeJuanita Draime
Juanita Draime
SBSarah Berman
Sarah Berman
JGJulia Gardner
Julia Gardner
ZKZach Krauss
Zach Krauss
JMJoe Martinez
Joe Martinez
Chronic disease prevalence is increasing. Adherence to dietary guidelines is low (<50%) despite positive impacts in disease progression, clinical outcomes, and medical costs. It is important to summarize the impact of providing medically-tailored meals to patients on adherence rates, clinical outcomes, and potential economic outcomes. A systematic review was conducted to identify, extract, and appraise food-provision studies from January 1, 2013-May 1, 2018 for heart disease, diabetes (DM), and chronic kidney disease (CKD). The key findings related to adherence and clinical outcomes were compiled. Published literature was utilized to determine the economic impact of key clinical outcomes. Across diseases, 100 articles (N = 43,175 patients) were included. Dietary adherence was considered “compliant” or ≥ 90% consistently. Significant (p < 0.05) clinical outcomes included 5–10% LDL reduction, 4-11 mmHg SBP reduction, 30% reduction in metabolic syndrome prevalence, 3–5% weight reduction, 56% lower CKD mortality rates, and increased dialysis-free time (2 years:50%, 5 years:25%, calculated cost savings of 80.6–94.3%). Literature review showed these outcomes would result in decreased: cardiovascular (CV) event risk (20–30% reduction: $5–11 billion annually), hospitalization costs ($1–8 billion), and dialysis rates (25–50% reduction: $14–29 billion annually). For heart failure patients, results include: 16% fewer readmissions (saving $234,096 per 100 patients) and a 38-day shorter length of stay (saving $79,425 per hospitalization). Providing medically-tailored meals significantly increases dietary adherence above 90% and allows patients to realize significantly better chronic disease control. Through this, patients could experience fewer complications (CV events, hospital readmissions and dialysis), resulting in significant annual US healthcare cost reduction of $27–48 billion.

1 May 2016 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
DADouglas C. Anderson
Douglas C. Anderson
Juanita DraimeJuanita Draime
Juanita Draime
TATimothy S. Anderson
Timothy S. Anderson

1 August 2017 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
PDF file
RWRebecca Widder-Prewett
Rebecca Widder-Prewett
Juanita DraimeJuanita Draime
Juanita Draime
GCGinger Cameron
Ginger Cameron
DADouglas Anderson
Douglas Anderson
MPMark Pinkerton
Mark Pinkerton
ACAleda M. H. Chen
Aleda M. H. Chen
Objective. To determine the impact of student or faculty facilitation on student self-assessed attitudes, confidence, and competence in motivational interviewing (MI) skills; actual competence; and evaluation of facilitator performance. Methods. Second-year pharmacy (P2) students were randomly assigned to a student or faculty facilitator for a four-hour, small-group practice of MI skills. MI skills were assessed in a simulated patient encounter with the mMITI (modified Motivational Interviewing Treatment Integrity) tool. Students completed a pre-post, 6-point, Likert-type assessment addressing the research objectives. Differences were assessed using a Mann-Whitney U test. Results. Student (N=44) post-test attitudes, confidence, perceived or actual competence, and evaluations of facilitator performance were not different for faculty- and student-facilitated groups. Conclusion. Using pharmacy students as small-group facilitators did not affect student performance and were viewed as equally favorable. Using pharmacy students as facilitators can lessen faculty workload and provide an outlet for students to develop communication and facilitation skills that will be needed in future practice.

28 October 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
KBKyrie Eleyson Baden
Kyrie Eleyson Baden
HMHalley McClain
Halley McClain
CCCraig Craig
Craig Craig
NGNathan Robert Gibson
Nathan Robert Gibson
Juanita DraimeJuanita Draime
Juanita Draime
ACAleda M. H. Chen
Aleda M. H. Chen
Background/Objectives: S-adenosylmethionine (SAMe) is a natural compound implicated in the treatment of liver dysfunction. In this systematic review, our objective was to determine the efficacy, safety, and optimal dose of SAMe in liver diseases. Methods: Using the PRISMA methodology, we searched PubMed, CINAHL, and Web of Science using key MeSH search terms. For title/abstract screening, full-text review, and data extraction, two independent researchers reviewed articles, and a third researcher resolved conflicts. Data extraction also included a quality assessment of included articles. Results: Of the 1881 non-duplicated studies, 15 articles focusing on SAMe use in the liver were included. All included studies (n = 15) scored a 4 or 5 out of 5 points on the quality assessment, which indicated high study quality. Overall, SAMe was effective in improving liver-related parameters with few adverse events, which were primarily mild, transient gastrointestinal complaints. Conclusions: The most common doses were SAMe 1000 mg or 1200 mg per day with or without another treatment or natural supplement. Future studies are needed to assess long-term efficacy and safety data of SAMe and the optimal route of administration in liver diseases.

1 May 2018 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
Juanita DraimeJuanita Draime
Juanita Draime
DADouglas C. Anderson
Douglas C. Anderson
TATimothy S. Anderson
Timothy S. Anderson

24 June 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
KBKyrie Eleyson Baden
Kyrie Eleyson Baden
SHSarah L. Hoeksema
Sarah L. Hoeksema
NGNathan Robert Gibson
Nathan Robert Gibson
DGDivine Gadi
Divine Gadi
CCCraig Craig
Craig Craig
ACAleda M. H. Chen
Aleda M. H. Chen
Background/Objectives: Glucosamine and chondroitin are natural substances often used alone or in combination for conditions affecting the joints. Our objective was to evaluate the efficacy and safety of glucosamine and/or chondroitin supplementation in humans as well as to determine the common dosages used. Methods: A systematic review was conducted using PRISMA methodology. Searches were performed in PubMed and Web of Science and uploaded into Covidence where two independent researchers reviewed articles according to inclusion and exclusion criteria. Quality assessment was performed using the Mixed Methods Appraisal Tool (MMAT). Results: Of the 2013 articles screened, 146 studies were included in our review, with nearly 60% being randomized controlled trials and most conducted in Europe, Asia, or the U.S. Most studies focused on osteoarthritis and joint pain, with over 90% of efficacy studies reporting positive outcomes and most safety studies indicating minimal or no adverse effects. Glucosamine and chondroitin were most commonly administered together at daily doses of 1500 mg and 1200 mg, respectively, and often compared to a placebo or celecoxib. Conclusions: Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain. Consistent dosing strategies and favorable safety profiles across a diverse range of studies support their continued use in clinical practice, but further research is needed related to other disease states.